Related Experiment Video
Updated: Sep 14, 2025

12:11
Methodology for Accurate Detection of Mitochondrial DNA Methylation
Published on: May 20, 2018
13.5K
Exploring biomarkers for noise-induced hearing loss through mitochondrial DNA methylation analysis
Dianpeng Wang1,2, Caiping Li1,2, Liuwei Shi2,3
1School of Public Health, Southern Medical University, Guangzhou, China.
Frontiers in Pharmacology
|July 21, 2025
Summary
Noise-induced hearing loss (NIHL) is linked to altered mitochondrial DNA methylation. The CYB gene shows potential as a biomarker for diagnosing NIHL.
Area of Science:
- Molecular Biology
- Genetics
- Audiology
Background:
- Noise-induced hearing loss (NIHL) is a prevalent occupational disease.
- Occupational noise exposure damages cochlear cells via mitochondrial oxidative stress and reactive oxygen species (ROS).
- Mitochondrial dysfunction and apoptosis are key mechanisms in NIHL pathogenesis.
Purpose of the Study:
- To investigate the impact of noise-induced oxidative stress on mitochondrial DNA methylation.
- To identify potential molecular biomarkers for NIHL.
- To explore the relationship between mitochondrial DNA methylation patterns and NIHL.
Main Methods:
- Genome-wide methylation sequencing of mitochondrial DNA was performed on 40 NIHL cases and 40 controls.
- Targeted region sequencing utilized bisulfite multiplex PCR capture and high-depth next-generation sequencing (NGS).
- Analysis focused on differential methylation sites within mitochondrial genes.
Main Results:
- Significant differences in mitochondrial DNA methylation were observed at 53 sites in NIHL cases compared to controls.
- Lower methylation levels were found in genes like ATP6 and CYB in the NIHL group.
- The CYB gene demonstrated high diagnostic potential with an AUC of 0.807 in ROC analysis.
Conclusions:
- Mitochondrial DNA methylation, particularly in ATP6 and CYB genes, is reduced in individuals with NIHL.
- The CYB gene methylation pattern emerges as a promising potential biomarker for NIHL diagnosis.
- Further research is warranted to explore complex interactions and develop advanced diagnostic and therapeutic strategies for NIHL.

